Treatment Action Group Adds Three New Board Members
As it celebrates its 30th Anniversary year, Treatment Action Group (TAG) announced the election of David Puente, Michael Montero and Ivy Kwan Arce to its Board of Directors.
As it celebrates its 30th Anniversary year, Treatment Action Group (TAG) announced the election of David Puente, Michael Montero and Ivy Kwan Arce to its Board of Directors.
Pipeline Report provides an overview of research and provides an overview of research and development of innovations for diagnosing, preventing, treating, and curing HIV, hepatitis C virus (HCV), and tuberculosis (TB).
Save the date for Tuesday, November 16, 2021! TAG’s 2021 Research in Action Awards will honor some of the best and brightest activists, scientists, and leaders in the fight to end HIV, tuberculosis, and hepatitis C across the U.S. and around the world. This year we’ll once again gather virtually to ensure this year’s event is safe and open for participation to our allies and friends across the U.S. and world.
In response to this morning's announcement by the New York City Department of Health and Mental Hygiene (NYC DOHMH) that the DOHMH would open a temporary monkeypox vaccination clinic at the Chelsea Sexual Health Clinic in New York, Treatment Action Group's Executive Director, Mark Harrington, and TAG HIV Project Director Riko A. Boone, MSW, MPH, MA, said:
This year we celebrate the unending dedication and accomplishments of TAG’s staff. They persevered through the challenges of an ongoing pandemic in 2021 to find new ways to carry out our work.
On May 18, 2022, Treatment Action Group (TAG), the Black AIDS Institute (BAI), and the Southern AIDS Coalition (SAC) participated in this fun and informative Instagram Live discussion commemorating HIV Vaccine Awareness. Day.
Treatment Action Group (TAG) today mourns the premature loss of transformative LGBTQ and AIDS activist Urvashi Vaid, formerly executive director of the National Gay and Lesbian Task Force (now the National LGBTQ Task Force) at the height of the U.S. AIDS crisis in the late 1980s and early 1990s, and peerless leader of the LBGTQ movement for many years thereafter.
A group of six leading HIV/AIDS and viral hepatitis advocates today released the following joint statement regarding recent manufacturer action against the 340B Drug Pricing Program:
At the first of these two public hearings TAG submitted the following statement with six reasons why the new international instrument must explicitly acknowledge the right to science as a central guiding framework.
On April 15 TAG presented, "HIV Updates From CROI: The Good, the Bad, and the Long-Acting." This free webinar unpacked the most significant developments in HIV research presented at the Conference on Retroviruses and Opportunistic Infection (CROI), and what they mean for communities affected by HIV.